Speaker(s): 

Fady Gendy, DO, Medicine Pediatric Resident, Geisinger - has nothing to disclose.

Moderator(s): 

Michaelyn Notz, DO, Staff Member, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Describe current global and U.S. epidemiologic trends in Hepatitis C infection, including high-risk populations and shifting transmission patterns
• Explain the natural history and pathophysiology of Hepatitis C, including common clinical presentations and complications such as cirrhosis and hepatocellular carcinoma
• Interpret key laboratory tests including viral load, genotype/subtype, fibrosis staging, and LFT patterns--to guide clinical decision making
• Identify first-line and alternative treatment options with direct-acting antivirals (DAAs), including indications, contraindications, drug interactions, and expected cure rates
• Discuss emerging research and future directions, including novel antivirals, vaccine development, micro-elimination strategies, and approaches to screening and linkage to care 

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Michaelyn Notz, DO; Jeffrey Summers, DO and Shriraj Patel, DO have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None